Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial
Nutrients · 10.06.2025 · 17 (12) · 1972
DOI: 10.3390/nu17121972 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 10.06.2025. Verfasst von Metha Yaikwawong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Hauptthemen laut MEDLINE: Curcumin, Diabetes Mellitus, Type 2, Inflammation, Fatty Liver. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thailand Research Fund, Ministry of Public Health.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Curcumin, a bioactive polyphenol derived from turmeric, has demonstrated potential therapeutic effects in metabolic dysfunction-associated steatotic liver disease (MASLD) by modulating inflammation, oxidative stress, hepatic fat accumulation, and fibrosis.
Objective
To evaluate the efficacy of curcumin in reducing hepatic steatosis and liver stiffness in patients with MASLD.
Methods
In this randomized, double-blind, placebo-controlled trial, 78 patients with type 2 diabetes mellitus (T2DM) and MASLD were randomly assigned to receive either curcumin (1500 mg/day) or placebo for 12 months. The primary outcome was the change in tumor necrosis factor (TNF) levels. Secondary outcomes included changes in interleukin-1 beta (IL-1β), interleukin-6 (IL-6), antioxidant enzyme activities (glutathione peroxidase, superoxide dismutase), the oxidative stress marker malondialdehyde, non-esterified fatty acids, and hepatic parameters (hepatic steatosis and liver stiffness). Assessments were conducted at baseline and at 3, 6, 9, and 12 months.
Results
All participants completed the study (curcumin group: n = 39; placebo group: n = 39). Curcumin significantly reduced TNF levels at all follow-up points compared to placebo (p < 0.001). IL-1β, IL-6, and malondialdehyde levels also declined significantly (p < 0.001), while antioxidant enzyme activities, including glutathione peroxidase and superoxide dismutase, increased significantly (p < 0.001), indicating improved oxidative balance. Furthermore, curcumin led to significant reductions in non-esterified fatty acids, total body fat, BMI, hepatic steatosis, and liver stiffness compared to placebo.
Conclusions
Twelve months of curcumin supplementation improved glycemic control, reduced systemic inflammation and oxidative stress, and significantly improved hepatic steatosis and liver stiffness in patients with MASLD. These findings support curcumin as a promising adjunctive therapy for MASLD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
- Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
- Faculty of Pharmacy, Silpakorn University, Nakhon Prathom 73000, Thailand.
- Division of Endocrinology and Metabolism, Faculty of Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.
ORCID-Profile: Metha Yaikwawong, Somlak Chuengsamarn
Förderung
- Thailand Research Fund
- Ministry of Public Health
Zitieren
APA
Yaikwawong, M., Jansarikit, L., Jirawatnotai, S., & Chuengsamarn, S. (2025). Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial. Nutrients, 17(12), 1972. https://doi.org/10.3390/nu17121972
Vancouver
Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S. Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial. Nutrients. 2025;17(12):1972. doi:10.3390/nu17121972
BibTeX
@article{Yaikwawong2025,
author = {Yaikwawong, Metha and Jansarikit, Laddawan and Jirawatnotai, Siwanon and Chuengsamarn, Somlak},
title = {Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial},
journal = {Nutrients},
year = {2025},
volume = {17},
number = {12},
pages = {1972},
doi = {10.3390/nu17121972}
}
EUVIMED